Brain metastases (BM) from pancreatic ductal adenocarcinoma (PDAC) are an infrequent event. We identified 25 patients with a median age of 58 years from Memorial Sloan Kettering Cancer Center with BM and PDAC. Median time to the development of BM was 17 months (range, 0-79 months); median overall survival from the time of BM development was 1.5 months (range, 1-31 months). Six patients underwent germ-line testing, with BRCA1 (n [ 1) or BRCA2 (n [ 2) alterations detected, and 7 patients underwent molecular profiling, with KRAS, TP53, and MYC amplification the most frequent. Purpose: To assess clinical characteristics of patients with metastatic pancreas ductal adenocarcinoma (PDAC) and brain metastases (BM), and to assess somatic and germ-line molecular profiles where performed. Patients and Methods: Patients with PDAC and BM between January 1990 and January 2016 were identified. Molecular characteristics of somatic and germ-line testing where performed in the subset of patients who had provided informed consent. Somatic alterations were assessed by either MSK-IMPACT testing (>340 key cancer genes) or Sequenom testing (8-gene panel). Overall survival was calculated from date of diagnosis to either date of last follow-up or death. Survival after BM was calculated from date of diagnosis of BM by radiology or pathology to either date of last followup or death. Results: From a total of 5824 patients with PDAC identified from January 2000 to January 2016, twentyfive patients (0.4%) had BM. Median age at PDAC diagnosis was 58 years. Median time to the development of BM from initial PDAC diagnosis was 17 months (range, 0-79 months). Median overall survival after BM diagnosis was 1.5 months (range, 1-31 months). Overall survival for patients who had craniotomy (n ¼ 4) was 11 months (range, 1-31 months), with 2 long-term survivors at 21 and 31 months, respectively. Four patients had leptomeningeal disease. Six of 25 patients had germ-line testing, and 3 had BRCA mutations (2 BRCA1 and 1 BRCA2). Somatic profiling identified KRAS mutations in 100% (4 G12D, 2 G12V, and 1 Q61K). Conclusion: BM from PDAC is a rare event. We identified a speculative association of germ-line BRCA1/2 alterations with BM in PDAC, which requires corroboration. Survival after BM development is poor; prolonged survival occurred in selected patients via a multidisciplinary approach.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer-related death, with an estimated 53,070 cases occurring in the United States in 2016. 1 PDAC is a challenging disease, with the majority of patients presenting with either locally advanced or metastatic disease at the time of diagnosis. Metastatic disease from PDAC is more commonly evident at sites such as the liver, lymph nodes, peritoneum, and lung. In contrast, brain metastases (BM) from PDAC are rare, with a reported incidence of < 0.6%. 2, 3 Given that PDAC has an aggressive tumor biology and an adverse prognostic outlook, a possible hypothesis for the rarity of BM in PDAC is that patients do not survive long enough for BM to develop or become clinically apparent. After death, BM from PDAC have been described both in a case report 4 and in a larger series with a rate of 7.9%, 5 suggesting that the actual rate of < 0.6% may be low.
Furthermore, since 2011, modest clinical therapeutic progress has been made in PDAC with cytotoxic chemotherapy regimens such as leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIR-INOX) 6 and the doublet regimen of gemcitabine and nab-paclitaxel, 7 thus improving survival compared to single-agent gemcitabine therapy in patients with metastatic disease. We hypothesized that the ability to achieve longer systemic disease control through sequencing of active agents may result in a more frequent incidence of clinically evident BM. We reviewed records of patients with PDAC evaluated at Memorial Sloan Kettering Cancer Center over a 16-year period to identify patients with BM to determine associated clinical, pathologic, and molecular features and to describe this entity's natural history.
Materials and Method

Samples
A retrospective review of patients evaluated at Memorial Sloan Kettering Cancer Center with BM from PDAC from January 2000 to January 2016 was undertaken from several prospectively maintained databases after institutional review board review. Charts were reviewed to determine clinicopathologic characteristics, including age at diagnosis, disease stage at presentation, treatment of primary tumor, use of chemotherapy (neoadjuvant, adjuvant, or metastatic settings), and management of BM (surgery or radiotherapy). In addition, molecular characteristics were determined via somatic and germ-line testing, where performed, in the subset of patients who had provided informed consent. Somatic alterations were assessed by either Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) testing (> 340 key cancer genes) or Sequenom testing (8-gene panel).
Statistical Analysis
Overall survival was calculated from the date of diagnosis to either date of last follow-up or death. Survival after brain metastasis was calculated from the date of diagnosis of BM by radiology or pathology to either date of last follow-up or death.
Target Capture and Sequencing
Molecular profiling was performed by the MSK-IMPACT assay, which detects mutations and copy number alterations using DNA derived from frozen and formalin-fixed, paraffin-embedded tissue. 8 The assay has been designed to sequence all coding exons of > 340 cancer-associated genes and to provide 98% power to detect mutations with a true variant allele frequency of 10%, novel mutations down to a threshold of 5% variant allele frequency, and mutations at recurrent hot spots down to a threshold of 2% variant allele frequency. Before the introduction of MSK-IMPACT testing in 2014, a Sequenom mass spectrometry panel, which included 8 genes assessing for hot spot mutations in AKT1, BRAF, EGFR, ERBB2, KRAS, MAP2K1, NRAS, and PIK3CA genes, was utilized.
Results
Clinical Characteristics
From a total of 5824 patients with PDAC identified from January 2000 to January 2016, twenty-five patients (0.4%) had BM. Seventeen patients (68%) had locally advanced or metastatic disease at initial diagnosis. Clinical characteristics are outlined in Table 1 . Men were more frequently affected (60%), with a median age at pancreas adenocarcinoma diagnosis of 58 years (range, 44-79 years). The median time to the development of BM from initial diagnosis of pancreas adenocarcinoma was 17 months (range, 0-79 months). All patients had evidence of BM by computed tomography or magnetic resonance imaging (Figures 1 and 2 ). The most common indication for central nervous system imaging was headache (36%, 9/25). Other neurologic symptoms that prompted imaging included facial or limb weakness (16%), visual disturbance (12%), ataxia (8%), and seizure (8%). One patient underwent imaging for persistent nausea. Another patient had a diagnosis of BM incidentally discovered as part of a workup of a concurrent diagnosis of diffuse large B-cell lymphoma and stage IV pancreas Brain Metastases in PDAC adenocarcinoma. Biopsy of the brain lesion confirmed that the central nervous system lesion was of pancreatic origin. BM were evident at time of initial diagnosis of metastatic disease in 3 patients. All patients developed extracranial disease at some point during their disease trajectory. One patient developed a solitary BM 17 months after initial diagnosis of stage III pancreas adenocarcinoma but developed peritoneal disease 12 months after craniotomy. The majority (68%, n ¼ 17) had evidence of liver metastases at the time of metastatic presentation, followed by lung metastases (52%, n ¼ 13) and peritoneal disease (20%, n ¼ 5).
Treatment
First-line systemic chemotherapy regimens are listed in Table 2 . The mean number of systemic treatments was 2 (range, 0-8). 
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Six patients had received prior adjuvant therapy, 4 had received single-agent gemcitabine, and one patient each had received adjuvant gemcitabine, docetaxel, and capecitabine and FOLFIRINOX. The treatment modalities used in 24 patients with available followup of their BM are outlined in Table 2 . Four patients (16.6%) underwent craniotomy and 15 (62.5%) received radiotherapy. Eight patients (33.3%) received only best supportive care. Of the patients who received radiotherapy, the majority (n ¼ 13) received wholebrain radiotherapy, with 2 patients receiving stereotactic radiosurgery. Median overall survival for all patients after diagnosis of BM was 1.5 months (range, 1-31 months). Median overall survival of 4 patients after craniotomy was 11 months (range, 1-31 months). Location of BM varied, with > 50% having evidence of frontal lobe involvement. Four patients had evidence of leptomeningeal disease (LMD), and 5 (21%) had cerebellar metastases (Table 2) .
Molecular Testing
Seven patients had somatic mutational profiling: 4 had MSK-IMPACT, and 3 had Sequenom testing (8-gene panel) (Figure 3) . KRAS mutations were detected in all 7 cases. Six of 7 KRAS mutations were located at codon 12, four of which were KRAS G12D and 2 KRAS G12V mutations. One patient had a KRAS Q61K mutation. Sample origins for molecular testing for MSK-IMPACT included skin (n ¼ 1), lung (n ¼ 1), pancreas (n ¼ 1), and brain (n ¼ 1). For patients who had the limited 8-gene panel, one sample each was from brain, pleura, and pancreas.
Two patients with BM from PDAC were known BRCA1/2 carriers. Four other patients had germ-line BRCA testing; one had a BRCA2 V211I germ-line alteration. The germ-line mutation status of the other 19 patients was unknown. 
Discussion
To our knowledge, this is the largest reported series to date of BM in patients with PDAC. Previously reported cases, including case reports and a single-institution experience, 9 are summarized in Table 3 . Consistent with prior data reported, men were more frequently affected in our data set and represented 60% of patients. Median age at the time of pancreas adenocarcinoma diagnosis within our patient cohort was 58 years (range, 44-79 years), similar to a previously reported median age of 61.5 years. 9 The median time to development of BM was 17 months for the 24 patients within our data set, 1 year shorter than the 29 months reported previously. 9 Notably, our series included a higher number of patients with locally advanced or de novo metastatic disease at presentation: 71% (17/24 patients) compared to 11% (1/9 patients). 9 No patients had ampullary carcinoma. We sought to identify somatic genetic alterations in PDAC that may have predisposed the patient to develop BM. In a prior series, TP53 mutations were detected in 3 patients with BM, and all were wild-type SMAD4 by immunohistochemistry. 9 In a cohort of 10 patients with ERBB2-amplified PDAC cases, 1 of 8 patients with metastatic disease developed BM. 21 In our data set, we identified KRAS mutations in all patients; they were predominantly located at codon 12 in 86% (n ¼ 6) cases. TP53 was altered in 2 of 4 patients who had broader profiling by MSK-IMPACT in our data set. We did not identify any ERBB2 mutations in either the 8-gene panel or ERBB2 amplifications/mutations by broader MSK-IMPACT testing. Two patients in this data set had molecular testing performed on their BM (Figure 1 ). Both harbored codon 12 KRAS mutations. Concurrent TP53 and RB1 loss in one patient sample coexisting with KRAS by MSK-IMPACT, which would indicate a possible small-cell phenotype. 22 Additionally, the presence of a GNAS R201 mutation concurrent with a KRAS G12V mutation in one patient implies that this tumor likely arose from a precursor intraductal pancreatic neoplasm. 23 This patient developed BM 70 months after diagnosis of a stage IIA tumor, and 54 months after diagnosis with metastatic disease consistent with a more favorable biologic profile. 24 Similarly, a case report of oncocytic carcinoma derived from an intraductal pancreatic neoplasm and metachronous BM harbored a KRAS G12V mutation with the presence of GNAS mutation not remarked upon. 11 MYC amplification was noted in 2 of 4 samples by MSK-IMPACT ( Figure 3 ) and has been reported as an inducer for metastases in in vivo models of lung cancer.
25
A novel aspect to our cohort was the finding of germ-line BRCA1/2 in 3 of 6 patients who underwent germ-line testing. Germ-line BRCA1 alterations have been associated with an increased propensity for BM in breast cancer 26 and ovarian cancer. 27 Germ-line BRCA1/2 mutations have not been associated with BM in PDAC to date. We anticipate that ongoing prospective studies in patients with BRCA1/2-associated PDAC will contribute more information in this regard. Specifically, data from our group and others have demonstrated the potential value of platinum-based therapies and poly(ADP-ribose) polymerase inhibitors in patients with germ-line BRCA mutations. [28] [29] [30] Because these patients may live longer compared to patients without germ-line BRCA mutations, they theoretically may be at a higher risk of developing rarer sites of metastases, including BM. Survival is poor for most patients upon development of BM, with rare exceptions in select patients who undergo resection, with longterm survival reported in 3 patients who had oligometastatic disease. 9, 14 Median survival after brain metastasis was 1.5 months in our data set. For the selected patients who had resection within our described cohort, a longer median survival after diagnosis of BM was noted of 11 months (range, 1-31 months). Two patients survived more than 1 year after BM development-21 and 31 months, respectively. Both had surgical resection and received subsequent systemic chemotherapy. One patient had a solitary brain metastasis resected, followed by gemcitabine, docetaxel, and capecitabine chemotherapy and 2 subsequent lines of therapy upon systemic progression. The other patient who experienced long-term survival underwent resection of a dominant mass, followed by whole-brain radiotherapy, followed by 2 lines of chemotherapy. Both patients died of extracranial disease. Less common sites of central nervous systemerelated disease from PDAC reported in the literature include the presence of LMD and cerebellar metastases. LMD from PDAC has been described at the initial presentation of PDAC, [31] [32] [33] both in the presence 20 and absence 34 of parenchymal BM. Four patients had evidence of LMD, all of which occurred late in the disease trajectory with parenchymal BM. Additionally, cerebellar metastases have also been reported. 9, 12 They were evident in 5 patients in our data set.
Conclusion
To our knowledge, this is the largest reported clinical data set of BM in PDAC. BM from PDAC are rare and not exclusively seen in patients with prolonged survival. Indeed, the minority (32%, n ¼ 8) of patients within our data set had evidence of BM after 2011, which is after the introduction of both FOLFIRINOX and gemcitabine plus nab-paclitaxel for metastatic PDAC, suggesting no definitive increase in incidence since these regimens have been introduced. We provide insights into the somatic and germ-line alterations identified in patients who had molecular testing. While acknowledging small numbers of subjects who underwent germ-line testing in this data set, a putative association of BM with germ-line 
Abbreviations: BM ¼ brain metastases; NR ¼ not reported; OS ¼ overall survival; RT ¼ radiotherapy; SRS ¼ stereotactic radiosurgery.
Brain Metastases in PDAC e320 -Clinical Colorectal Cancer June 2018 BRCA1/2 alterations was noted. Survival is poor upon metastatic brain disease development; however, in select patients, long-term survival can be achieved utilizing a multidisciplinary approach to treatment, highlighted by 2 long-term survivors. With advances in germ-line and somatic profiling, our findings of a possible association of germ-line BRCA1/2 alterations as well as other molecular patterns may provide insight into the molecular features of this uncommon clinical entity.
Clinical Practice Points
BM from PDAC are a rare event, with a frequency of 0.4% in our series. BM confer a poor prognostic implication, with a median survival after diagnosis of BM of 1.5 months (range, 1-31 months).
In select patients, long-term survival can be achieved when incorporating a multidisciplinary approach. For example, the median survival for the 4 patients who were able to undergo craniotomy after BM development was 11 months (range, 1-31 months), with 2 patients surviving more than 1 year (21 and 31 months, respectively). The molecular profile of patients who develop BM from PDAC is poorly understood. Our results indicate a speculative association of BM in PDAC with germ-line BRCA1/2 alterations, which occurred in 3 of 6 patients who underwent germ-line testing.
Somatic profiling was performed in 6 patients and identified KRAS mutations in all of them: G12D (n ¼ 4), G12V (n ¼ 2), and Q61K (n ¼ 1), with TP53 mutations and MYC amplification occurring most commonly in 2 of 4 patients who had broader profiling by MSK-IMPACT. Median time to development of BM was 17 months (range, 0-79 months), with 3 patients harboring de novo BM involvement. This indicates that the development of BM is not confined to patients with PDAC who experience long-term systemic disease control.
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